CD34 and acute myeloid leukemia: Whether to investigate associations between WT1-mRNA levels and AML disease severity and prognosis, WT1 expression was assessed at diagnosis, during therapy, and follow-up, and levels were correlated with complete blood counts (CBCs) and flow cytometer counts (percentage of granulocytes, percentage of CD34+ cells, and NBC).